FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Media News)
Source: Roche Media News - November 13, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Roche today announced that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting from 1-4 December, 2018. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)
Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Media News)
Source: Roche Media News - October 29, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche today announced that the US Food and Drug Administration (FDA) has approved Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. (Source: Roche Media News)
Source: Roche Media News - October 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Roche will today announce results from the phase III ALESIA study, showing that Alecensa ® (alectinib) met its primary endpoint of investigator-assessed (INV) progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche today announced positive results from the Phase III IMpower130 study of Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy help ed people live significantly longer compared to chemotherapy alone (median overall survival [OS] =18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) populatio...
Source: Roche Media News - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Roche today announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours. (Source: Roche Media News)
Source: Roche Media News - October 21, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Media News)
Source: Roche Media News - October 20, 2018 Category: Pharmaceuticals Source Type: news

Roche reports very strong growth in the first nine months of 2018
Group sales increase 7% at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Alecensa and Tecentriq. Diagnostics Division sales grow 6%, primarily due to demand for immunodiagnostic solutions. (Source: Roche Media News)
Source: Roche Media News - October 17, 2018 Category: Pharmaceuticals Source Type: news

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
Roche today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO Tumor Tissue Targeted Kit, Expanded Kit and Surveillance Kit. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from 10 October to 12 October in Berlin, Germany. (Source: Roche Media News)
Source: Roche Media News - October 10, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
Roche today announced that new results from a number of studies across its industry leading oncology portfolio of approved and investigational medicines will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place from 19-23 October, in Munich, Germany. (Source: Roche Media News)
Source: Roche Media News - October 9, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors
Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - October 4, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Roche today announced that the phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median time of 73.2 hours versus 102.3 hours; p (Source: Roche Media News)
Source: Roche Media News - October 4, 2018 Category: Pharmaceuticals Source Type: news

Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche today announced interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in SMA. (Source: Roche Media News)
Source: Roche Media News - October 3, 2018 Category: Pharmaceuticals Source Type: news

Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany, 10 to 12 October. (Source: Roche Media News)
Source: Roche Media News - October 2, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Roche announced today the global availability of FoundationOne ®Liquid, a liquid biopsy test. (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
Roche today announced the launch of the first two NAVIFY ® clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps help oncology care teams access relevant clinical trial information and publications more effectively. (Source: Roche Media News)
Source: Roche Media News - September 18, 2018 Category: Pharmaceuticals Source Type: news

Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running
For the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). (Source: Roche Media News)
Source: Roche Media News - September 13, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
Roche today announced that new data from its broad clinical development programme across different types of lung cancer will be presented at the International Association for the Study of Lung Cancer (IASLC) 2018 World Conference on Lung Cancer (WCLC), taking place from 23 –26 September in Toronto, Canada. (Source: Roche Media News)
Source: Roche Media News - September 6, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
Roche today announced that pivotal data from the phase III HAVEN 3 study, which evaluated Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with haemophilia A without factor VIII inhibitors, were published in the 30 August 2018 issue of the New England Journal of Medicine (NEJM). (Source: Roche Media News)
Source: Roche Media News - August 30, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Corporate Executive Committee
Roche today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. (Source: Roche Media News)
Source: Roche Media News - August 28, 2018 Category: Pharmaceuticals Source Type: news

China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - August 20, 2018 Category: Pharmaceuticals Source Type: news

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington ’s disease
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine RG6042 (formerly known as IONIS-HTTRx) for the treatment of people with Huntington’s disease (HD). (Source: Roche Media News)
Source: Roche Media News - August 3, 2018 Category: Pharmaceuticals Source Type: news

Roche Purchases Shares in Tender Offer for FMI
Roche and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche ’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.0 0 per share in cash. (Source: Roche Media News)
Source: Roche Media News - July 31, 2018 Category: Pharmaceuticals Source Type: news

Roche reports very strong performance in the first half of 2018
Group sales increase 7% at constant exchange rates and in Swiss francs (Source: Roche Media News)
Source: Roche Media News - July 26, 2018 Category: Pharmaceuticals Source Type: news

Roche receives CE Mark for its Accu-Chek Solo micropump system
Roche announced today that it has received CE Mark for its Accu Chek ® Solo micropump system. (Source: Roche Media News)
Source: Roche Media News - July 23, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data demonstrating the breadth and depth of its Alzheimer ’s programme at the upcoming Alzheimer's Association International Conference
Roche announced today that it will present 16 new data presentations from across its Alzheimer ’s disease (AD) pipeline at this year’s Alzheimer's Association International Conference (AAIC) from 22-26 July in Chicago, Illinois. (Source: Roche Media News)
Source: Roche Media News - July 20, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease
Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s dis ease (AD) or other causes of dementia. (Source: Roche Media News)
Source: Roche Media News - July 20, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - July 19, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)
Source: Roche Media News - July 18, 2018 Category: Pharmaceuticals Source Type: news

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu
Roche today announced that the phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study ’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo The Centers for Disease Control and Prevention (CDC) defines people at high risk for serious flu complications to include adults 65 years of age or older, or thos e who have conditions such as asthma, chronic lung disease, diabetes, or heart disease – for these people, flu can lead to hospitalisation ...
Source: Roche Media News - July 17, 2018 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. (Source: Roche Media News)
Source: Roche Media News - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - July 2, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
Roche today announced that the Phase III IMpower133 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis. (Source: Roche Media News)
Source: Roche Media News - June 25, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Enlarged Corporate Executive Committee
Roche today announced that Sophie Kornowski-Bonnet, Head of Roche Partnering and member of the enlarged Corporate Executive Committee since 2012, has accepted a new opportunity and will be leaving the company effective 31 July 2018. (Source: Roche Media News)
Source: Roche Media News - June 22, 2018 Category: Pharmaceuticals Source Type: news

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
Roche and Foundation Medicine, Inc. today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI ’s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. (Source: Roche Media News)
Source: Roche Media News - June 19, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis
Roche today announced that new OCREVUS (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology (EAN) from 16 June to 19 June in Lisbon, Portugal. (Source: Roche Media News)
Source: Roche Media News - June 14, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection. (Source: Roche Media News)
Source: Roche Media News - June 13, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - June 5, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Media News)
Source: Roche Media News - June 2, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 1, 2018 Category: Pharmaceuticals Source Type: news